Podcasts about Wharton

Alan's Soap https://AlansSoaps.com/ToddHonor John's memory and the legacy he created for Ian and Alan with Alan's Artisan Soaps “John's Favorites” bundle.  Get one bar of each of his favorites for only $28.99. Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bonefrog https://BonefrogCoffee.com/ToddGet the new limited release, The Sisterhood, created to honor the extraordinary women behind the heroes. Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeA paper from the Wharton school of business says unless a specific tax is installed, AI will destroy the country. Zach Abraham of Bulwark Capital Management joins to help us break it down.Episode Links:Plans released for a $16 billion mile-long ship capable of carrying 80,000 people. The 'Freedom Ship' would be home to about 50,000 people, with space for 10,000 tourists and 20,000 crew members.

As we enter summer, we talk about how applicants can strategically approach those early MBA application dates. Plus, we demystify the ‘career vision'. 

In this episode of The Yegi Project, Barbie Wharton shares her journey from experiencing Bell's palsy to becoming a motivational coach and podcast host. She discusses the importance of using your voice, handling life's seasons, and building authentic connections to live a fulfilled life.Connect with Barbie!Instagram: https://www.instagram.com/realtalkbarbie/Website: https://www.barbiewharton.com/ Takeaways* Using your voice for personal growth* Handling life's seasons and challenges* Building authentic relationships and communityIf you would like to be a guest on a future episode of The Yegi Project, please email info@yegiproject.comThe Yegi Project is available on Apple Podcasts, Spotify, Stitcher and more!https://linktr.ee/theyegiprojectDisclaimer: This podcast or any other The Yegi Project episodes on this platform or other podcast streaming platforms is not legal business or tax advice. I make this content based on my own experience as a business owner and MBA for educational and entertainment purposes only. #theyegiproject Podcast Audio & Video Edited by Elizabeth HadjinianInstagram - https://www.instagram.com/theyegiprojectTikTok - https://www.tiktok.com/@theyegiproject YouTube - https://www.youtube.com/@theyegiproject

We'll be back soon with new episodes. In the meantime, enjoy this episode about Jho Low, the fraudster who charmed Hollywood's elite while allegedly stealing over $4 billion from one of Malaysia's sovereign wealth funds.Jho Low, a Malaysian-born businessman, will do anything to climb the social ladder. After attending Wharton business school, he establishes himself as a globe-trotting playboy with a celebrity entourage. He uses his money to get near Leonardo DiCaprio, Miranda Kerr, Paris Hilton, Britney Spears, and Kim Kardashian. But the source of Jho Low's seemingly endless cash is a mystery…. Until one of his former associates decides to blow the whistle.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What makes a podcast feel authentic?In this episode, we sit down with Jennifer Moss, Co-Founder and Chief Creative Officer of JAR Podcast Solutions, one of the world's leading branded podcast agencies. Jennifer has helped organizations ranging from Amazon and Cirque du Soleil to Wharton create podcasts that do more than promote a brand—they tell stories that audiences genuinely want to hear.The conversation explores why so many brand podcasts fail to connect, what separates great storytelling from corporate messaging, and how brands can create audio content that builds trust, engagement, and long-term audience relationships.Jennifer also shares her perspective on the growing role of AI in content creation, why human-centered storytelling matters more than ever, and what she has learned leading creative teams at the forefront of the podcast industry.The PR Podcast is a show about how the news gets made. We talk with great PR people, reporters, and communicators about how the news gets made and strategies for publicity that drive business goals. Host ⁠⁠Jody Fisher⁠⁠ is the founder of Jody Fisher PR and works with clients across the healthcare, higher education, financial services, real estate, entertainment, and non-profit verticals. JAR Podcast Solutionswebsite: https://jarpodcastsolutions.comThe PR Podcast Facebook: https://www.facebook.com/ThePRPodcast/Twitter: https://x.com/ThePRPodcast1Instagram: https://www.instagram.com/theprpodcast_/TikTok: https://www.tiktok.com/@theprpodcast?

Most clinic owners lose 40 to 60% of their patients in the first 8 weeks. The enthusiasm fades, the patient self-discharges, and the practice quietly bleeds revenue it already paid to acquire.Dr. Jay Greenstein knows the math better than almost anyone. In 2003, his practices were growing fast and he was still going broke, because he understood clinical care but not systems, process, or collections. That crisis sent him to Wharton's small business program, into Jack Welch's playbook and Six Sigma, and eventually to building EMBODI: a platform that uses behavioral science, gamification, and AI to turn patient follow-through into measurable outcomes and practice income.In this episode, Jeff pushes Jay past the pitch and into the operational reality. You get the data, the billing mechanics, the hiring lessons, and the version that failed before any of it worked.What You'll Learn:- The exact retention numbers from 7 independent practices and over 4,000 patients (40.48% more visits, 36.12% more revenue for EMBODI users versus non-users)- How EMBODI qualifies as software as a medical device and opens 6 Remote Therapeutic Monitoring billing codes most owners are leaving on the table- Why rising patient acquisition costs make lifetime value the only number that matters, and how to engineer it- The "first who, then what" hiring philosophy Jay learned the hard way, and the resume-first mistake that cost him for years- What Jay would do to rebuild from zero in 30 days using today's AI toolsIf you got value from today's show, you know the only fee we ask: hit share and send this to one clinic owner who needs it.Want to talk through your own growth bottleneck? Book a call: https://api.leadconnectorhq.com/widget/bookings/discoveryroadmapcallpodcastyoutubeLearn more about EMBODI: https://embodihealth.com/Connect with Dr. Jay Greenstein: https://www.instagram.com/drjaygreenstein/Earnings disclaimer: Results discussed reflect the experiences of the guest and the specific practices studied. Individual results vary and are not guaranteed. Nothing in this episode is financial, legal, or medical advice.

What if luck is not random, but designed? In this episode of Leveraging Thought Leadership, Peter Winick sits down with Judd Kessler, Wharton professor and author of "Lucky by Design: The Hidden Economics You Need to Get More of What You Want." Judd's work brings market design out of the academic journal and into daily life. He studies the hidden systems that determine who gets access, who gets opportunity, and who gets left waiting. These systems are everywhere. School programs. Job assignments. Consulting projects. Ticketing platforms. Government services. Nonprofit resources. Even your own time and attention. Judd's thought leadership gives leaders a new lens. First, see the market. Then understand the rules. Then decide whether those rules are helping or hurting the outcomes you want. For organizations, this is not theoretical. Poorly designed internal markets create frustration, waste, and inequity. Better rules can improve allocation, retention, performance, and trust. Peter and Judd explore how a book can move academic insight into practical use. They also dig into the harder work after publication: building an audience, entering the cultural conversation, and turning expertise into influence. This conversation is a sharp look at how thought leadership scales when it makes invisible systems visible. And when it gives people the tools to redesign them. Three Key Takeaways: • See the hidden market. Many opportunities are shaped by invisible systems, from school programs and job assignments to access, attention, and scarce resources. • Design better rules. Poorly built systems create frustration, waste, and unfairness. Better rules lead to smarter outcomes. • Make ideas practical. Strong thought leadership turns complex concepts into tools people and organizations can actually use. If this conversation made you think differently about the hidden rules that shape behavior, go back and listen to our episode with Luke Battye. Both episodes explore how people make decisions inside systems they often do not see. Judd Kessler looks at hidden markets, scarcity, and the rules that determine who gets what. Luke Battye looks at behavior change, design thinking, and how small shifts in context can change what people do next. Together, these episodes give you a sharper lens for understanding systems, incentives, and behavior. You'll walk away with practical ways to design better outcomes for customers, teams, and organizations.

Ste is joined by Andy and Ian for our Liverpool Transfer Podcast to discuss the Reds targeting Adam Wharton from Crystal Palace and Yan Diomande from RB Leipzig, as well as the potential sale of Curtis Jones to Inter Milan.Get an exclusive 15% discount on Saily data plans! Use the code redmentv at checkout. Download the Saily app or go to: https://saily.com/redmentv ⛵ Hosted on Acast. See acast.com/privacy for more information.

I WAS THINKING:  The Difference Between Hobo and Homeless Cultures // Spotify CEO defends AI music, wants you to stop calling it 'slop'. David Solomon even played an AI-generated house track at Wharton. The No. 1 Song On U.S. iTunes—And Several Other Countries—Is AI Generated // “Star-Studded” Lineup Announced for Freedom 250 Celebration

I WAS THINKING:  The Difference Between Hobo and Homeless Cultures // Spotify CEO defends AI music, wants you to stop calling it 'slop'. David Solomon even played an AI-generated house track at Wharton. The No. 1 Song On U.S. iTunes—And Several Other Countries—Is AI Generated // “Star-Studded” Lineup Announced for Freedom 250 Celebration

A fire sale? An arms race? However you term it, business schools are slashing rates – we look at how applicants can score a scholarship.

Hilary Dubin is co-CEO and head of Jones' digital product & behavioral support program. She graduated from the University of Pennsylvania magna cum laude, majoring in cognitive science with a concentration in computation and cognition, an honors thesis on the effects of gender, realism, and role of virtual agents, and a minor from Wharton in consumer psychology.  She worked in David Brainard's visual neuroscience lab for 3 years and published 4 papers and supplementary materials on illumination discrimination (color perception). After Penn, she was selected as one of ten Americans to be a Ventures Fellow in the Excel Ventures incubator program in Tel Aviv, and continued on to be the inaugural member, and later program lead, of the US Associate Product Manager Program at Atlassian.  She worked as a product manager at Atlassian for 5 years, ultimately as Head of Confluence Editions & Admin Experience where she launched Confluence Premium & Free into multi-million dollar product offerings with 2M+ users. She hired & managed two PMs and lead a team of over 30 developers.  Prior to founding Jones, she and Caroline founded Cozier together, a sleep & loungewear brand designing ethical, effortlessly chic garments for every/body. Hilary started vaping casually in 2017 when the JUUL seemed relatively harmless and fun.  When the world went on lockdown in 2020, her casual vaping habit became a daily crutch for coping with stress and working from home. After over a year of unsuccessful cold-turkey quit attempts, she finally kicked her vaping habit in 2022 when Caroline suggested she try NRT.  Outside of work, Hilary loves hiking, backcountry skiing, trying to find the best burger in NYC, and playing with other people's dogs. In This Conversation We Discuss: [00:00] Intro [02:34] Creating products from personal pain points [06:52] Sponsor: Klaviyo  [08:59] Meeting potential customers where they are [10:47] Adapting products based on user feedback [13:48] Testing market demand with waitlists [16:02] Sponsor: Electric Eye [17:10] Maximizing personal networks for growth [18:34] Gathering behavioral data in early days [19:52] Callouts [20:02] Launching a product to engaged audiences  [22:09] Sponsor: Intelligems [24:09] Pivoting marketing to bridge early limitations [26:24] Driving organic traffic with relatable content  [30:33] Adding modern value to traditional products Resources: Subscribe to Honest Ecommerce on Youtube Nicotime mints and social app to quit vaping quitwithjones.com/ Follow Hilary Dubin linkedin.com/in/hilary-dubin-374156b4/ Follow Caroline Vasquez Huber linkedin.com/in/caroline-vasquez-huber Book a demo today at intelligems.io/ Schedule an intro call with one of our experts electriceye.io/connect Get your free demo klaviyo.com/honest If you're enjoying the show, we'd love it if you left Honest Ecommerce a review on Apple Podcasts. It makes a huge impact on the success of the podcast, and we love reading every one of your reviews!

This podcast was taped at a conference where I hosted several Penn Professors on a variety of topics. The audience included my friends who will join me in asking questions.Our speaker is Phil Tetlock who is a Professor at Wharton and the author of a book entitled Superforecasting. Often, we get our news and analysis from experts who make predictions that are terribly wrong. Phil has analyzed methods of forecasting and has found individuals and groups who are fantastic predictors of politics, war, and sports.I want to learn how AI and superforecasters working together will revolutionize the prediction process and why that is helpful to markets and mankind. Get full access to What Happens Next in 6 Minutes with Larry Bernstein at www.whathappensnextin6minutes.com/subscribe

To speak with an advisor and build a smarter college admissions strategy, book a Complimentary Strategy Call at:

Adam Wharton scored his first goal for Crystal Palace at Brentford, much to the delight of his Mum who danced to the tune of the Selhurst sound in the away end. Terence, Albert and Hesketh look back at the 2-2 draw in West London, look ahead to Arsenal's visit to South London and cover 'Spygate', Mother doing very Well and whether or not the latest managerial shuffle points Iraola towards the Palace dugout. Hosted on Acast. See acast.com/privacy for more information.

Dr. Deb Muth 00:04What if the future of healing isn’t about replacing cells, but about teaching your body how to heal itself again? We keep hearing the words stem cells and exoomes thrown around like they’re interchangeable, but they’re not. One is regulated, controversial, and often misunderstood. The other is rapidly emerging as one of the most exciting communication systems in human biology. Dr. Deb Muth 00:33And here’s the real question no one’s asking. Are we actually regenerating tissue or are we just stimulating the body to remember how it used to heal? Tired of being told your labs are normal, but you still feel terrible? At Serenity Healthcare Center, we don’t chase symptoms. We find the root cause. hormones, gut health, autoimmune conditions, chronic fatigue, brain fog. Dr. Deb Muth 01:02We use cuttingedge functional and regenerative medicine to get you real answers and a real path forward. This isn’t your average doctor’s office. This is medicine the way it was meant to be practiced. You deserve to feel like yourself again. Visit serenityhealthcarecenter.com to book your appointment today. Let us help you heal from the inside out. Dr. Deb Muth 01:28Welcome back to Let’s Talk Wellness Now. I’m Dr. Deb, your host. And if you’ve been following regenerative medicine, you’ve probably noticed the confusion. Patients are asking me every week, are exoomes stem cells? Are stem cells legal in the United States? I heard the FDA is shutting down all these clinics. Can I even get this therapy? Do I have to leave the country for treatment? Today, we’re cutting through the noise. This episode is not hype. Dr. Deb Muth 01:54It’s not sales. It’s education so you can understand the science, the regulatory reality, and the clinical difference between stem cell therapy and exoome therapy. And here’s what I want you to know right up front. Yes, these therapies are being used in the United States every single day. Yes, they’re being offered by highly trained physicians in integrative and regenerative medicine clinics across the country. Dr. Deb Muth 02:22Some are being used in FDA registered clinical trials. Some are being used in observational studies and some are being used in clinical practice under physician discretion. The landscape is nuanced and you deserve to understand it. So, grab your cup of coffee or tea and settle in for a deep dive into the most understood therapies in regenerative medicine. Dr. Deb Muth 02:43what they actually are, how they work, the regulatory landscape, and how they might support your body’s natural healing capacity. Let’s talk wellness now. So, let me start by asking you something. When you hear the word stem cell, what do you picture? Most people imagine damaged tissues magically regenerating or a torn meniscus growing back, cartilage reforming it into an arthritic joint or damaged brain tissue being replaced with healthy new beautiful cells. It’s a beautiful vision. Dr. Deb Muth 03:15And while it’s not quite that simple, the reality is actually more sophisticated and honestly more beautiful. Stem cells are powerful and they absolutely work, but the way they work and the mechanism by which they support healing is far more elegant and more so than most people really understand. And if you’re going to invest in regenerative therapy, you deserve to understand what you’re actually receiving. Dr. Deb Muth 03:44So, let’s start at the beginning. What are stem cells? At their core, stem cells are undifferentiated cells. That means they haven’t yet decided what they want to be when they grow up. Unlike a heart cell or a skin cell or a bone cell which have already committed to a specific function, stem cells exist in this beautiful state of potential. Dr. Deb Muth 04:05They have two remarkable abilities. First, they can self-renew. They can make copies of themselves, maintaining a reserve of these powerful cells throughout your lifetime. Second, they can differentiate under the right conditions. They can transform into specialized cell types. Bone cells, cartilage cells, nerve cells, muscle cells, even blood cells. Dr. Deb Muth 04:27This is why they’ve captured the imagination of the medical world. The potential is extraordinary. Now, there are several types of stem cells and understanding the differences matters tremendously for both understanding how they work and understanding how they’re regulated. Adult mezzenymal stem cells. We call these MSC’s are the most commonly used regenerative medicine. Dr. Deb Muth 04:54These come from bone marrow, atapost tissue, that’s fat, and other adult sources. They’re what we can call multi-potent, meaning they can become several types of cells, but not every type. A bone marrow stem cell isn’t going to become a brain cell, for instance. It has potential but it’s directed potential. Dr. Deb Muth 05:19Then we have perinatal stem cells. These come from umbilical cord blood cord tissue or something called Wharton’s jelly which is the gelatinous substance inside the umbilical cord. These cells are younger, more potent, and research by Weiss and colleagues published in stem cells back in 2006 showed that Wharton’s jelly derived MSC’s have superior proliferation and differentiation potential compared to bone marrow derived cells. Dr. Deb Muth 05:48They’re like comparing a 20-year-old athlete to a 50-year-old athlete. Both can perform, but one has more reserve capacity, more vigor, and more regenerative potential. And this isn’t this is very important because the perinatal sources umbilical cord tissue Wharton’s jelly amniotic tissue these are what many regenerative medicine clinics in the United States are using today and they’re using them because these tissues are incredibly rich in not just stem cells but growth factors cytoines and exoomes. Dr. Deb Muth 06:21Then there are embryionic stem cells. These are pur potent and they become any cell type in the body, but they’re highly regulated, ethically controversial, and honestly, they’re not being used in clinical practice in the United States outside of the very specific FDA approved research trials. Dr. Deb Muth 06:41So, when clinics talk about stem cell therapy, they’re almost never talking about embryionic stem cells. Now, here’s where it gets interesting and this is the part that changes everything about how we understand regenerative medicine. When you receive stem cell therapy, let’s say someone injects umbilical cord derived messenymal stem cells into your arthritic knee, those cells do not typically engraft or become new tissue in any permanent way. Dr. Deb Muth 07:12They don’t set up shop in your joint and start cracking out new cartilage cells for the rest of your life. So what are they actually doing then? Well, in 2011, researchers Arnold Arnold Kaplan and Dennis Korea published a landmark paper in stem cells translational medicine that fundamentally changed how we understand MSC therapy. Dr. Deb Muth 07:35They proposed that we should stop calling memal stem cells and start calling them medicinal signaling cells. Why? Well, because their primary therapeutic benefit doesn’t come from what they become. It comes from what they secrete. Think of stem cells as incredibly sophisticated biological pharmacies. When you inject them into damaged tissue, that arthritic knee, that inflamed autoimmune condition, that injured brain, that don’t just sit there passively, they sense the environment. Dr. Deb Muth 08:07They detect inflammation. They recognize the tissue damage and they understand that the immune dysregulation is present and they see that and respond. They start pumping out hundreds of bioactive molecules, growth factors that tell your cells to repair and rebuild, cytoines that modulate inflammation, chemocines that recruit your body’s own healing cells to the area. Dr. Deb Muth 08:32And these tiny membranes bound packages called extracellular vesicles, including exosomes, which we’re going to talk about extensively today as well. These secreted factors are giving instructions to your native cells. They’re saying, “Let’s reduce inflammation. Let’s modulate your immune response. Let’s promote angioenesis. Dr. Deb Muth 08:53” That’s the formation of new blood vessels, bringing nutrients and oxygen. Let’s stimulate your own resident stem cells to wake up and get to work. Reduce cell death in damaged tissue and restore normal cellular function. This is called paracrine signaling. It’s the cellto cell communication. And this is where the real therapeutic power lives. Dr. Deb Muth 09:14The stem cells themselves, many of them die within days to weeks, but the cascade of healing they trigger, the signals they send, the programs they activate in your own cells, those effects can last for months or even years. Now, this understanding is crucial because it explains why both stem cell therapy and exoo therapy can be effective. Dr. Deb Muth 09:38The stem cells are powerful not because they become new tissue but because of the signals they send and exoomes are those signals isolated and concentrated. The biggest misconception in regenerative medicine is that stem cells replace tissue and in reality they coach healing more than they become healing. They’re biological educators teaching your body to remember how it used to heal before chronic inflammation, toxicity, and disease turned off all those programs. Dr. Deb Muth 10:12So if stem cells don’t exactly end graft and become the new tissue, if their power is in their signaling and then next logical question is why do we need the cells at all? Well, if we could isolate the messengers themselves, what if we could deliver just the communication systems without any of the complexity of the living cells? Well, that’s exactly what exosomes are. Dr. Deb Muth 10:38And they represent the cutting edge of regenerative medicine. So, let me paint you a picture of how cells actually communicate. Because for most medical history, we had it wrong. For decades, textbooks taught us that cells talk to each other in two basic ways. through direct contact like shaking hands or releasing signaling molecules that floated through the extracellular space like messages in bottles, simple chemical messages. Dr. Deb Muth 11:09But in the 1980s and 90s, researchers started discovering something far more sophisticated. cells were releasing these tiny membrane bound packages like a biological FedEx envelope kind of you know it was filled with complex specific cargo and these packages could travel through the blood cross the barriers that normally keep things out like bloodb brain barrier and deliver their contents to distant cells with remarkable precision. Dr. Deb Muth 11:38These are called extracellular vesicles. And exoomes are one of the most therapeutic important types. So what exactly are exosomes? Well, they’re nanosized vesicles, typically 30 to 150 nanome in diameter. To put that into perspective, a human hair is about 100,000 nanometers wide. These are incredible and most impossibly tiny. Dr. Deb Muth 12:09They’re released by virtually all cells in the body, but the most therapeutically interesting exoomes come from mezenymal stem cells. And those medicinal signaling cells we just discussed. And according to a landmark review of Raposo and Stervogal, they published in the journal of cell biology in 2013, exoomes are not cellular debris. They’re not waste products. Dr. Deb Muth 12:35They are precisely engineered communication vesicles or vehicles. Think of them as sophisticated delivery systems carefully packed, carefully labeled, and sent to specific destinations. very specific instructions. Inside each of these exoomes, you’ll find an incredibly sophisticated payload. They are microRNAs. These are small RNA molecules that can literally turn genes off or on in the recipient cells. Dr. Deb Muth 13:06They can tell a cell to start making more collagen, to reduce inflammatory proteins, to activate repair programs that have been shut down by chronic disease for a very long time. There are messenger RNAs, actual templates for protein production. And exoome can deliver these instructions for making healing proteins. There are proteins themselves, growth factors, cytoines, enzymes, all the molecular tools a cell needs to heal. Dr. Deb Muth 13:34And there are lipids, specialized fats that help the exoome membrane fuse with targeted cells, delivering the cargo inside. When an exoome reaches its target cell, it can either fuse the cell membrane and deliver its contents directly inside like a Trojan horse, or it can bind to surface receptors and trigger signaling cascades, setting off a chain reaction of healing responses. Dr. Deb Muth 14:01Either way, it’s delivering very specific targeted instruction. And here’s what makes this so powerful. Those instructions are tailored to what this recipient cell actually needs. So, let me give you some concrete examples of what the research actually shows because this is where it really gets exciting. When researchers inject MSC derived exoomes into hearts that had experienced eskeeia, reprofusion, injury, that’s damaged blood flow being cut off and then being restored. Dr. Deb Muth 14:36Kind of like what happens during a heart attack. Something remarkable happened. A study by Lei and colleagues published in stem cell research in 2010 showed that exoomes significantly reduced the size of the damaged area, reduced inflammatory cytoines that drive tissue destruction and promoted tissue repair signaling. The exoomes were telling the heart cells stop the inflammatory cascade, activate your survival programs and repair the damage. Dr. Deb Muth 15:06In cartilage research, tow and colleagues published work in biioaterials in 2017 showing that exosomes derived from MSC’s could promote cartilage regeneration in osteoarthritis models. And the exoomes carried specific microRNAs that told condondroytes cartilage cells to proliferate and make more extracellular matrix, the structural framework of healthy cartilage. Dr. Deb Muth 15:30for autoimmune conditions. Research by Blazic and colleagues in Frontiers in Immunology in 2014 demonstrated that MSC derived exoomes could shift immune cell behavior from pro pro-inflammatory to regulatory. They could take an overactive self-attacking immune system and restore balance and promote tolerance. And perhaps most exciting brain research, a study by Zinn and colleagues published in the journal of extracellular vesicles in 2013 showed that MSC derived exoomes could cross the bloodb brain barrier. Dr. Deb Muth 16:07That protective shield around your brain that normally keep things out and promote neurological recovery in stroke models. They reduced brain inflammation, promoted neuroplasticity, supported the formation of neural connections, and for mitochondrial dysfunction, which underlies so many chronic conditions, Morrison and colleagues published research and scientific reports in 2017 showing that MSC derived exoomes can actually deliver functional mitochondria or mitochondrial components to damaged cells. They’re not Dr. Deb Muth 16:40just sending instructions, they’re sending spare parts. They’re restoring the cellular powerhouses to produce energy. So why are exoomes fundamentally different from stem cells? Well, exoomes contain no living cells. They can’t replicate. They can’t end graph. And they have virtually no risk of immune rejection or tumor formation. Dr. Deb Muth 17:03Concerns that exist elevate rarely with cellular therapies. They’re essentially biological software updates for your cells. As Fineian Pitiger wrote in their seinal review in stem cells in 2017, MSC derived exoomes represent the active ingredient of stem cell therapy delivered in a cellfree format. That’s the key insight in the in the therapeutic benefit of stem cells and it comes from what they excrete. Dr. Deb Muth 17:33Then exoomes are the secretion isolated, concentrated, and standardized. From a practical clinical standpoint, exoomes offer several compelling advantages. First, consistency. Because exoomes can be isolated, characterized, and standardized, each dose can be remarkably consistent. With living stem cells, there’s variability based on donor age, health status, processing methods, and one batch may be robust, but another might be weaker. Dr. Deb Muth 18:05With exoomes, you can measure the content, measure the potency, and ensure the quality control. Second is storage. Exoomes can be liophalized. They can be freeze-dried and stored at room temperature or refrigerated for extended periods. Stem cells require cryopreserv preservation, careful freezing, careful thawing. They’re fragile. Dr. Deb Muth 18:31Exoomes are remarkably stable. And third, their safety profile. Without living cells, the risk of adverse imunological reactions is dramatically lower. You’re not introducing foreign cells that your immune system might recognize and attack. You’re introducing molecular messages. Fourth is scalability. You can harvest millions, even billions of exoomes from stem cell cultures without ever injecting the cells themselves. Dr. Deb Muth 19:01And you can produce large quantities, standardize them, and make them available to patients. Now, there is a caution here in doing this. The scalability can produce rogue cells, and we want to be cautious of that. So, here’s what I need you to understand. Exoomes don’t force healing. They remind the body how healing works. Dr. Deb Muth 19:24They’re not replacing damaged cells. They’re re-educating the cells you already have. They’re turning back time on the biological programs that got turned off by inflammation, toxicity, trauma, time, and chronic disease. Your body knows how to heal. It’s done its entire life. Every cut that closed, every bone that mended, every infection you fought off, your body orchestrated that healing. Dr. Deb Muth 19:51The problem is that chronic disease, chronic inflammation, toxic exposures, poor nutrition, stress, all of these things disrupt the communication networks that coordinate healing. And exoomes restore that communication. They’re like rebooting a computer that’s frozen. They reset the system and remind it how it’s supposed to function. All right. Dr. Deb Muth 20:14So, this would not be complete if we didn’t talk about regulation because this is where a lot of confusion exists. And I want you to be given a real picture. Not fear-mongering, not pretending. There aren’t regulatory considerations, but the actual practical reality of how regenerative medicine is practiced in the United States today. Dr. Deb Muth 20:38Here’s what you need to understand. The FDA regulates these therapies and they have specific frameworks, but there’s important nuances between regulatory text enforcement priorities and actual clinical practice. And there are also state level regulations that provide additional pathways. The FDA regulates human cells, tissues, and cellular and tissue based products. Dr. Deb Muth 21:05We call them HCT/PPS under two main pathways. Section 361 products are those that meet specific criteria. They’re minimally manipulated, intended for homologous use, meaning these tissues perform the same basic function in the recipient as it did in the donor. They’re not combined with non-tissue components and they’re either autotogus, meaning they come from your own tissue, or they have had minimal systemic effect. Dr. Deb Muth 21:38An example of a clear 361 procedure, your doctor harvests your own bone marrow, we call this PRP, performs minimally processing to or uh perform Yeah. performs minimal processing to concentrate the stem cells through a centriuge and injects it into your arthritic knee the same day. That’s autogus same day but minimally manipulated. Dr. Deb Muth 22:04This is unquestionably legal and is being done in regenerative medicine clinics across the country every single day. So there’s section 351 where products are those that don’t meet all the section 361 criteria. They’re classified as drugs or biologic products and they require FDA approval through clinical trials. Dr. Deb Muth 22:27Now here’s where this gets more nuanced. There are regenerative medicine clinics across the United States using stem cell and exoome therapies in different contexts. First FDA registered clinical trials. These are formal research studies with investigational new drug applications. Patients enroll in trials. They sign informed consents. Dr. Deb Muth 22:48They receive therapies as part of their structured research protocols. And this is completely legal and represents the gold standard for gathering evidence. Second is observational studies and registry programs. Many clinics are collecting systemic data on patient outcomes using these therapies even outside the FDA trials. Dr. Deb Muth 23:12They’re documenting results, tracking safety, and contributing to the growing body of clinical evidence. Third, there’s clinical practice under physician discretion. There are physicians using these therapies based on their own clinical judgment informed consent from patients and their interpretation of the regulatory framework particularly around minimal manipulation and homologous use. Dr. Deb Muth 23:34Now there are also state regulations that provide additional legal frameworks. So, for example, Florida has enacted the Right to Try Act and specific regenerative medicine legislation that allows physicians to offer certain stem cell therapies under the state oversight. Utah has passed similar legislation creating pathways for regenerative medicine products. Dr. Deb Muth 23:57And these state laws recognize that patients should have access to potentially beneficial therapies, particularly when used by trained physicians with appropriate informed consent. The regulatory question often centers around are these products minimally manipulated. Some products clearly are not. They’ve been cultured. Dr. Deb Muth 24:20They’ve been expanded in laboratories and those require FDA approval that they don’t have. The FDA has appropriately shut down clinics using those products. But there are other products that undergo processing that many physicians and manufacturers argue constitutes minimal manipulation. And these tissues are cleared, potentially fragmented or particulated to make them more suitable for injection, preserved using methods like cryopreservation or liophalization and packaged. Dr. Deb Muth 24:54But the cells are not cultured or expanded in the laboratory. The FDA has issued guidance suggesting that many of these processing steps constitute more than manipul minimal manipulation. But many physicians, particularly those who specialized in regenerative medicine for years, disagree with that interpretation and they believe that the processing qualifies as minimal manipulation and that the product should fall under section 361 when used for homologous purposes. Dr. Deb Muth 25:24Is there regulatory debate? Absolutely. The FDA and some clinicians have different interpretations of what constitutes minimal manipulation. But here’s the practical reality. There are hundreds of well-trained, bore certified physicians across the United States offering these therapies every single day. Dr. Deb Muth 25:42They’re doing so based on their understanding of the regulations, their clinical experience, their commitment to patient safety, and their belief that these therapies can help people who have exhausted conventional options. The FDA’s enforcement priorities have focused primarily on the most problematic cases. Clin clinics making blatant disease cure claims, products with documented safety issues, clear cases of cellular expansion and culture, or clinics operating with no medical oversight. Dr. Deb Muth 26:15Reputable regenerative medicine physicians are using products from companies that provide comprehensive documentation of their processing methods. third-party sterility testing, certificates of analysis showing bioactive content, and quality control measures that meet or exceed industry standards. Now, let me be very clear about something. Dr. Deb Muth 26:36Quality matters enormously. Not all stem cells and exoome products are created equal. Research by Burger and colleagues published in the Orthopedic Journal of Sports Medicine in 2021 analyzed 12 commercially available stem cell products and found that many contained zero viable cells, high levels of bacteria, endotoxins and inconsistent growth factor concentrations. Dr. Deb Muth 27:01This is why the company providing these biologic matters tremendously. You want products from manufacturers who provide transport documentation in sourcing and processing. Conduct third-party testing and sterility and potency. Offer certificates of analysis for each batch. Use standardized validated processing protocols. Dr. Deb Muth 27:24Have quality control measures that ensure consistency and don’t make outrageous cure claims or promise. The best regenerative medicine physician carefully vet their suppliers. They don’t use products from companies making unrealistic promises. They use products from manufacturers who are transparent, scientifically rigorous, and committed to quality. Dr. Deb Muth 27:46Now, you specifically ask about homologous use and collagen defects. So, let me address this directly for you. Under the FDA guidance, homologous use means the tissue performs the same basic function in the recipient as in the donor. So for connective tissue, tendons, ligaments, cartilage, fascia, all of that which are collagenrich structures using MSC’s or their derivatives could be considered homologous use. Dr. Deb Muth 28:17MSC’s in their native environment provide structural support to produce extracellular matrix including collagen. Using them to support healing in damaged collagen rich tissues like arthritic joints, torn tendons or degenerative ligaments is arguably the same basic function. So using exoomes derived from MSC’s to support collagen synthesis reduce inflammation and promote tissue healing in the same structures. Dr. Deb Muth 28:46Many practitioners argue this also qualifies as homologous use because you’re supporting the structure and function that MSC’s would naturally support. So here’s the bottom line on the regulatory reality. Regenerative medicine is available in the United States. It’s being offered by highly trained physicians in integrative and regenerative medicine clinics across the country. Dr. Deb Muth 29:11Some therapies are offered in FDA registered clinics and some are offered in observational studies. Some are offered in clinical practice under physician discretion, informed consent, and careful attention to safety. The regulatory landscape is evolving. There are ongoing discussions both federally and state levels about creating clearer pathways for these therapies. Dr. Deb Muth 29:32So, if you choose to go down this road, you want to work with physicians who understand the regulations, who use quality products from reputable manufacturers with rigorous testing and documentation, who are transparent about what they’re using and why, who discuss the current regulatory landscape honestly with you, and who prioritize your safety and truly informed consent above all else. Dr. Deb Muth 29:55This is not a lawless wild wild west. But it is also not as simple as everything is legal and unavailable. It’s a nuanced landscape that requires ethical knowledge. And these practitioners that have this knowledge have got to provide informed patients who understand both the potential benefits and the current regulatory context. Dr. Deb Muth 30:17So let’s have some fun here. Let’s talk about what really matters to you that are listening and that’s what conditions are being supported with these therapies. What does the research show and what are clinicians seeing in actual practice with patients? Because here’s what’s really important. We have both published research evidence and extensive clinical experience. Dr. Deb Muth 30:38And when the two align, that’s when we can feel confident and comfortable about using these approaches. So, let’s start where we have the most substantial evidence. joint health and muscularkeeletal conditions. For arthritis, we have good data. A systemic review by Tan and colleagues published in arthritis research and therapy in 2021 analyzed 20 randomized controlled trials in MSC therapy for knee osteoarthritis. Dr. Deb Muth 31:05They found significant improvements in pain and function particularly in mild to moderate disease. What’s really interesting is when researchers start analyzing whether it was the cells themselves or their secreted factors doing the work. They found that exoomeenriched preparations showed similar benefits to whole cell therapy. Dr. Deb Muth 31:26Now towen colleagues in the biioaterials paper from 2017 demonstrated that MSC derived exoomes could promote cartilage matrix synthesize and reduce inflammation markers. The exoomes carried microarnas that told cartilage cells to make more collagen and proteoglycans, the building blocks of healthy cartilage. Dr. Deb Muth 31:49In clinical practice, physicians are seeing patients with knee, hip, shoulder, and spinal arthritis, experiencing reduced pain, improved function, better motility, and in some cases, measurable improvements in their tissue. I want to share a story here with you because back in 2006, my husband was injured at work. Some of you might have heard me tell this story before. Dr. Deb Muth 32:11Um, he broke two discs in his back and underwent surgery very early on when we started using stem cells. They had put cages and plates in and they used MSC’s to put inside the cage to create a hardened bone so that he could have a fusion and hopefully not have any pain. At the time, what the physician didn’t realize or mistakenly did was he did not put any human bone mixed with these dead cadaavver bone MSC’s. Dr. Deb Muth 32:42And so the MSC’s never grew. They didn’t have anything to grow by. So the plates and the screws just kind of went back and forth for six months before he could see another physician that would look at him differently and understand what actually happened. That was very early on. Today we know so much more than we did before. Dr. Deb Muth 33:01Fast forward to 2014 when my husband was having problems and he couldn’t feel his legs, he couldn’t feel his feet. We decided to undergo uh exoo and stem cell therapy again and we saw a physician in Florida who harvested cells from his bone marrow and his blood and his fat and mixed that all together and then put that back into the back. Dr. Deb Muth 33:27and he had tremendous benefit from it. So, I tell this story because I want you to see the trajectory of how long this has been going on that we’ve been using this and we’re learning as we’re going and things are changing rapidly in this in this world. And so, what we know today and what I’m teaching you today may very well change in a month or six months or a year from now, but we have the foundation at least to understand what is helpful, what is not right now. Dr. Deb Muth 33:54But just be aware that if you’re embarking on exoome or stem cell therapy or MSC’s that you understand that this terrain is going to change. So back to my conversation about what other things can we treat? Well, we can treat tendon and ligament injuries, chronic tennis elbow, Achilles tendonopathy, rotator cuff tears, chronic planter fasciitis. Dr. Deb Muth 34:17These were researched by PA and colleagues in the American Journal of Sports Medicine in 2017 and it showed that bone marrow concentrate injections resulted in improved pain and function compared to steroid injections. Now this mechanism appears to be enhanced collagen remodeling and reduced chronic inflammation. Dr. Deb Muth 34:39These are structural collagenrich tissues using MSC’s or their derivatives for structural support which makes biological sense. It’s homologous use. It’s similar. So clinically we’re seeing athletes, active adults and people with chronic pain who failed physically um failed physical therapy, failed conservative treatments finding relief in this functional uh improvement in this functional world that we live in today. Dr. Deb Muth 35:07So, I want to be clear about what we’re doing here for joint and muscularkeeletal issues. We’re not growing completely new cartilage from scratch or severely destroyed joints. We’re not magically regenerating tissues that’s been gone for decades. That’s not possible here. What you’re doing when you’re using MSSE’s and exoomes is supporting the body’s natural ability to repair, reducing inflam inflammation and damage, and we’re driving progressive degeneration uh or we’re stopping the progressive degeneration. By reducing the Dr. Deb Muth 35:41inflammatory damage, we’re stimulating resonant stem cells that have been dormant. We’re improving blood flow and uh uh oxygen to the tissues like cartilage and tendons. and we’re organizing the body to start creating its own quality collagen as it heals. So, it’s a regenerative support, not a tissue replacement. Dr. Deb Muth 36:07But for many people, this support is lifechanging. So, let’s talk about autoimmune disorders now because this is one of the most exciting and unrecognized applications. autoimmune conditions like rheumatoid arthritis, lupus, MS, Crohn’s disease, ulcerative colitis, Hashimoto’s, they all involve the immune system and the immune system is deregulated. Dr. Deb Muth 36:30And so basically your immune system is seeing this tissue as foreign and it’s attacking it. These MSC’s and their exoomes have profound immune modulatory properties. They don’t suppress the immune system like steroids or imunosuppressive drugs. They modulate it helping to restore balance. So for rheumatoid arthritis, research by Weang and colleagues in stem cells translational medicine in 2016 showed that MSC derived exoomes could shift the balance of immune cells, reducing pro-inflammatory TH7 cells that drive joint disruption uh and increase Dr. Deb Muth 37:08regulatory TE-C cells that maintain immune tolerance. So for MS, a clinical trial by Kasus and colleagues published in archives of neurology back in 2010 evaluated autotogus MSC therapy and MS patients and they found evidence of reduced disease activity, improved neurological function and decreased inflammatory uh lesions on MRI scans. Dr. Deb Muth 37:34The proposed mechanism is MSC’s and their exoomes reduce inflammatory cytoine production promote regulatory imu immune populations support remination of damaged nerves that is rebuilding the protective coating around the nerve fibers and it reduces bloodb brain barrier permeability which prevents immune cells from attacking their brain and spinal cord. Dr. Deb Muth 38:02And so for inflammatory bowel disease, the research by Barnholm uh sorry Barnhorn and colleagues in gut in 2020 showed that MS cell MSC derived extracellular vesicles could support mucosal healing and reduce inflammation in the gut lining. They appeared to restore intestinal barrier function, healing that leaky gut and modulating local immune responses. Dr. Deb Muth 38:30So in clinical practice, physicians are seeing patients with autoimmune conditions, experiencing reduced disease flares, decreasing the need for imunosuppressive medications, improving energy and quality of life, and in some cases extending periods of remission. But here’s what I want you to understand. Dr. Deb Muth 38:52When you see these therapies for autoimmune conditions, we are supporting immune regulation and reducing inflammatory damage. We are not treating or curing the disease in a conventional sense. These therapies work best as part of a comprehensive functional medicine approach that also addresses gut health because 70% of your immune system lives in your gut and environmental triggers like mold, heavy metals, chemical toxins that can drive autoimmune responses, chronic infections that can trigger immune disregulation, stress and nervous system imbalance. And Dr. Deb Muth 39:29these nutritional deficiencies are necessary to help improve the immune function. So regenerative therapy without addressing root causes is like bailing water out of your boat without plugging the hole. You might get temporary relief, but the underlying problem still remains. So let’s talk about neurological conditions. Dr. Deb Muth 39:52And this is where the science gets truly fascinating. for traumatic brain injury and concussion. Research by Zang and colleagues in the Journal of Neurot Trauma in 2015 showed that MSC derived exoomes could reduce brain inflammation, promote neuroplasticity, that’s the brain’s ability to rewire itself and improve cognitive outcomes in animal models. Dr. Deb Muth 40:17The exoomes crossed the bloodb brain barrier, delivered neuroprotective proteins and microRNAs. They reduced inflammation, supported mitochondrial function in injured neurons and promoted both new blood vessels from new blood formation and neurogenesis and the birth of new neurons occurred. Neurological recovery requires a multi-systematic approach. Dr. Deb Muth 40:42Exoomes may support neural repair, but they work best combined with hormone optimization, growth hormone, testosterone, thyroid, pregnnolone, mitochondrial support compounds like NAD, CoQ10, PQQ, carnitine, all of those things that we use traditionally in functional medicine. Now for stroke recovery, there was research by Zinn and colleagues in the journal of extracellular vesicles that showed MSC derived exoomes reduced the size of brain damage and improved neurological recovery in animal models. There was a Dr. Deb Muth 41:19Parkinson’s disease study done by Kimoji and colleagues in the movement disorders in 2018 that suggested that MSSE derived exoomes could support dopamineergic neuron survival and those are the cells that die in Parkinson’s and it can help to reduce neuroinflammation. Clinically, physicians are seeing improvements in patients with postconussion syndrome, chronic traumatic brain injury, early stage cognitive decline, and other neurodeenerative conditions. Dr. Deb Muth 41:52These are not cures, but meaningful improvements in cognitive function, mood, energy, and quality of life. Now, let’s talk about autism spectrum disorder very carefully here because this is a very sensitive but very important topic for families. There have been several clinical trials that have explored MSC therapy for autism. Dr. Deb Muth 42:16Liv and colleagues published research in stem cell translational medicine in 2013 showing improvements in social interaction, communication, and behavioral symptoms in children with ASD who received cord blood MSC’s. Dawson and colleagues in 2017 conducted randomized trial autotogus cord blood infusion and found modest improvements in social communication particularly in children with higher baseline immune dysregulation. Dr. Deb Muth 42:47The proposed mechanisms for modulation of neuroinflammation support the mitochondrial function because many children with autism show evidence of mitochondrial dysfunction, reduction of oxidative stress, improvement in gut brain access dysfunction and modulation of immune dysregulation. In clinical practice, some physicians are seeing improvements in some children, better eye contact, increased language development, reduced sensory sensitivities, improved social engagement, but responses vary significantly, and we cannot predict which children will benefit most. So for Dr. Deb Muth 43:26families considering regenerative approaches for autism, these therapies are supporting the body’s healing mechanisms, reducing neuroinflammation, supporting cellular energy production, modulating immune function. These should only be considered as part of a comprehensive biomedical approach that includes dietary interventions to address food sensitivities, support gut health, environmental toxin removal, particularly heavy metals and chemical exposures, gut healing protocols with targeted probiotics and nutrients, Dr. Deb Muth 44:00metabolic testing and targeted supplementation, and evidence-based on behavioral and developmental therapies. These therapies should only be pursued with practitioners who are honest about what we know and what we don’t know and who follow rigorous safety protocols who never promise cures and who view regenerative medicine as a tool in the comprehensive healing strategy, not a standalone miracle. Dr. Deb Muth 44:26Not only that, these therapies will most likely need to be given several times over the course of this person’s lifetime, possibly even on an annual basis. And this is really important because it is not a oneandone. It is not a one-sizefits-all, and it needs to be looked at as a long-term option for working with autism. So, since we’re looking at stem cells versus exoomes, living cells, with stem cell therapy, you’re receiving living cells that can survive in your body for days to weeks. Dr. Deb Muth 45:02With exoome therapy, there are no living cells, just biological messages they would have sent. So, replication stem cells can potentially replicate. Although therapeutically this happens minimally, exoomes cannot replicate. They deliver the cargo and then they are cleared by your body. With stem cells, it’s primarily paracrine signaling. Dr. Deb Muth 45:28They’re coaching your cells to heal. With exoomes, it’s pure signaling, pure reprogramming your cells without any cellular component. Stem cells as we talked about can be autotogus from your own bone fat, blood or um bone marrow or allergenic from umbilical cord tissue or Wharton’s jelly. Dr. Deb Muth 45:50Exoomes are typically derived from cultured MSC’s often from umbilical cord or bone marrow sources and both can be given by local injection for targeted treatment of joints and tissues and exoomes can be given intravenously for whole body systemic support. both have um low immun immunogicity. I can’t say that word today. Dr. Deb Muth 46:17But exoomes have even lower risk since they contain no cellular material. Now, it’s absolutely critical for you to understand that there are massive quality differences. We’ve talked about this earlier. I want you to be very aware of this and have a conversation with any of the practitioners that you’re considering undergoing this treatment with. Dr. Deb Muth 46:37Here is where it matters more than anything when you’re considering regenerative medicine, the quality of the products and the expertise of the practitioner. Because the reality is not all regenerative medicine products are created equal. We all know that when we take different supplements and not all practitioners understand these therapies at the same depth. Dr. Deb Muth 46:58You want to look for practitioners that are board certified or have some kind of specialized regenerative medicine training. You want to know their clinical experience. How much have they done these procedures? How long have they done this? You want honest communication about the evidence and the limitations in this. Dr. Deb Muth 47:17You want a comprehensive functional medicine approach to go along with these therapies. And you want somebody that’s transparent about their informed consent and their regulatory status. If you have people that are uh claiming that they can cure disease or giving you guarantees, that is not that is not a good practitioner to work with. Dr. Deb Muth 47:37If you have high pressure sales tactics, you need to decide today limited supply for a week. These are marketing manipulations. It’s not medical care. You want to be cautious of extremely low prices because quality regenerative products are expensive to source, process, and test. and store. And if somebody’s offering stem cells or exoomes for a few hundred dollars, seriously, you need to question the quality, the safety, and where they got this from. Dr. Deb Muth 48:09So before undergoing any regenerative therapy, make sure you’re having a very, very lengthy conversation with the person and so you truly understand exactly what you’re getting, how it’s going to be delivered, and what they’re going to do. If there’s one thing I want you to take away from today is that your body has remarkable capacity to heal when given the right biological signals and the right environment. Dr. Deb Muth 48:35Stem cells and exoomes are powerful tools for providing biological signaling that can reduce inflammation, modulate immune function, support tissue repair, and restore cellular communication that’s been disrupted by chronic disease and inflammation. These therapies are available in the United States through trained physicians working in FDA registered trials, observational studies, and clinical practice, and using quality products from manufacturers with rigorous testing and quality control. Dr. Deb Muth 49:04So before you invest in regenerative medicine, do your homework. Ask detailed questions about product quality and source. Verify the products come from reputable manufacturers with certificates of analysis, third-party testing. Work with experienced practitioners. And remember, no injection, no infusion, no biologic can overcome ongoing toxic exposure, chronic stress, poor nutrition, gut dysfunction, and inadequate sleep. Dr. Deb Muth 49:34True healing requires your body and you to actively participate in this healing. If you are unwilling to address the root causes and change the lifestyle factors that disrupted your health in the first place, the biologics can amplify your healing signals, but you have to create the internal environment where healing can actually happen. Dr. Deb Muth 49:56So, I hope this episode has helped you understand regenerative medicine more clearly. Share it with somebody who’s looking for healing beyond the conventional approaches. And until next time, this has been Let’s Talk Wellness Now. Have a blessed day. >> Welcome to Let’s Talk Wellness Now, where we bring expert insights directly to you. Dr. Deb Muth 50:16Please note that the views and information shared by our guests are their own and do not necessarily reflect those of Let’s Talk Wellness Now, its management, or our partners. Each affiliate, sponsor, and partner is an independent entity with its own perspectives. Today’s content is provided forformational and educational purposes only and should not be considered specific advice, whether financial, medical, or legal. Dr. Deb Muth 50:41While we strive to present accurate and useful information, we cannot guarantee its completeness or relevance to your unique circumstances. We encourage you to consult with a qualified professional to address your individual needs. Your use of information from this broadcast is entirely at your own risk. Dr. Deb Muth 51:00By continuing to listen, you agree to indemnify and hold Let’s Talk Wellness Now and its associates harmless from any claims or damages arising from the use of this content. We may update this disclaimer at any time, and changes will take effect immediately upon posting or broadcast. Thank you for tuning in. We hope you find this episode both insightful and thought-provoking. Listener discretion is advised.The post Episode 265 – The Future of Healing: How Exosomes Re-Educate Your Body to Heal Itself first appeared on Let's Talk Wellness Now.

Charlotte Observer's Carolina Panthers beat reporters Mike Kaye and Alex Zietlow offer thoughts on what the Turk Wharton injury means for the team (0:50) and whether a free agent option makes sense (9:05) Then, they go over some of the favorite match-ups (11:10) and least favorite match-ups (15:10) from last week's schedule release before outlining the OTA battles to watch (18:10). Learn more about your ad choices. Visit megaphone.fm/adchoices

The 2026 NFL schedule is out. Join Curtis Rauen, Bryson Karbley and Ricky Raines as they breakdown the Panthers games weeks 1-18. They also discuss rookie minicamp, Bryce Young's contract and Tershawn Wharton's injury. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

We talk over the picks on Poets&Quants's inaugural Career & Admissions Bestseller List, from ‘How to Win Friends and Influence People' to ‘What Colour is Your Parachute'. 

In the second hour, Mac & Bone continue to recap the weekend, as Mac rants about the All-Star Race at Dover, and they weigh in on the latest Rory McIlroy on the golf course, they talk about the impact of Turk Wahrton going on the PUP list, and what's next for the defensive line, before they give their conclusions from the weekend See omnystudio.com/listener for privacy information.

Did the Carolina Panthers completely miscalculate the trenches? In this episode, we break down why signing former Kansas City Chiefs defensive lineman Tershawn "Turk" Wharton to a massive 3-year, $54 million contract might officially go down as the biggest mistake of the Dan Morgan front-office era.While Morgan and Dave Canales have this team on the rise—even securing an NFC South division title—the metrics on Wharton tell a much harsher story. From struggling heavily against the run to ranking near the bottom of Pro Football Focus (PFF) interior defender grades, the analytics simply don't match the heavy price tag. To make matters worse, Wharton's ongoing battle with the injury bug—including a recent major neck surgery that has placed him on the PUP list—leaves a glaring, expensive hole in Ejiro Evero's defense.We look at the hard stats, the catastrophic run-defense liabilities, the pass-rush win rates, and the massive opportunity cost that forced Morgan to pivot and trade up for rookie Lee Hunter in the NFL Draft. Was this the ultimate evaluation blind spot for the Panthers' front office? Let us know your thoughts in the comments!Like, comment, and subscribe for more deep-dive NFL and Carolina Panthers analytics!

Ben and Matt discuss CPFC's trip to Manchester & the 2-2 draw in London. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The 2026 NFL schedule is officially locked in, and we are breaking down every single matchup, prime-time window, and brutal road stretch facing the Carolina Panthers this season! But the schedule drop isn't the only massive news coming out of Charlotte. The front office officially wrapped up its rookie draft class by signing second-round defensive tackle Lee Hunter to his four-year rookie deal. Unfortunately, that rookie signing becomes instantly critical following the devastating news that veteran lineman Tershawn "Turk" Wharton is out indefinitely after undergoing neck surgery. We dive into how Hunter and the rest of the defensive rotation will adapt, and give our way-too-early record predictions for the year ahead. Keep pounding!

Brentford's European hopes are still alive — just — after a dramatic draw against Crystal Palace at the Gtech.The Bees twice came from behind with Dango Ouattara grabbing both goals, including a late leveller that sent Lionel Road into full voice. Palace had looked sharp for long spells though, with Sarr's early penalty and Wharton's second-half strike putting the Eagles in control at different stages.Billy Grant spoke to Bees and Palace fans straight after the final whistle about the fightback, the nervy defending, the substitutions that changed the game, and whether it was a point gained or two dropped with Liverpool up next.European permutations. Frustration. Relief. Hope. It's all still on the table. Hosted on Acast. See acast.com/privacy for more information.

In this episode of Capital for Good we speak with Marla Blow, the president and CEO of the Skoll Foundation, the leading philanthropy focused on social entrepreneurship and innovation around the world. Over the course of this conversation, we learn how Blow's career in finance and financial inclusion, across the private and public sectors, would prepare her to lead a dynamic institution and community of innovators in this era of extraordinary change — and resilience.   We begin with important elements of Blow's origin story, including her childhood outside of Atlanta, a city (then) on the precipice of rapid growth, where she was drawn to the idea of helping people translate opportunity into long-term financial security. "I thought I could help people make better decisions," she said. That instinct would carry her to Wharton, Wall Street, an MBA at Stanford, and to Capital One, where she learned the discipline of applied behavioral economics and consumer lending. In the Obama Administration, Blow joined the Consumer Financial Protection Bureau, where she began to see more clearly the full landscape of American consumers — including those who were not well served by the traditional financial system or many of its products. That realization led her to found FS Card Inc to provide fairly priced credit to underserved consumers, an experience Blow describes as a "crash course" in entrepreneurship and the capital markets. Following the successful sale of FS Card, Blow helped lead Mastercard's Center for Inclusive Growth, where she was able to pursue financial inclusion at scale.   Blow speaks candidly about the extraordinary moment in which she assumed the CEO role at Skoll in 2025. The dismantling of USAID and broader cutbacks of support to and from multilateral finance institutions sent seismic shocks through the social entrepreneurship ecosystem that Skoll has supported since 1999. "I don't think any of us could have predicted that things would shift in this magnitude, or that they would shift this quickly," she says. And yet, Blow also describes with great admiration the resilience of individuals and organizations "that have been able to figure out how to pivot," efforts the foundation supported with a $25 million "pivot fund." Blow draws on the analogy of a forest of seemingly freestanding trees that are deeply interconnected beneath the surface. "It's the roots that enable them to transmit nutrients, to transmit information, to rebuild and regrow after absorbing and experiencing a shock," she says.   We also discuss a signature dimension of Skoll's work: the role of catalytic capital in driving impact. Today, approximately 80 percent of Skoll's endowment, managed in partnership with the Capricorn Investment Group, is aligned with the foundation's impact objectives in climate change mitigation and resilience, economic opportunity, health care, and responsible stewardship. Blow explains that these kinds of investments are not concessionary — their "financial returns continue to meet or exceed the performance of comparable asset classes" — and are exemplified by social enterprises like Apis & Heritage Capital Partners, a 2025 Skoll Award recipient that transitions small businesses to employee ownership – and has enabled main street workers to increase their net worth by a factor of ten.   We close with Blow's sources of optimism. They begin, she explains, with community — the cross-ideological partnership emerging across philanthropy, the private sector's increased engagement, the deep networks built over more than two decades of convening social entrepreneurs at the Skoll World Forum. "We are going through something, it's going to take a toll," she says. "And there is a light on the other side of it. We can continue working toward that light."   Mentioned in this episode: The Skoll Foundation Skoll World Forum Transformation and Renewal in the Impact Ecosystem, The Skoll Foundation 2026 Annual Letter Capricorn Investment Group Evolving Philanthropy for Collective Action, (Stanford Social Innovation Review, Blow & Gips, 2024) Apis & Heritage Capital Partners Consumer Financial Protection Bureau Mastercard Center for Inclusive Growth  

Join Tess Michaels, Founder and CEO of Clasp, for a strategic discussion on solving one of the most critical crises in modern infrastructure: the healthcare staffing shortage. With a high-octane background in healthcare investment banking at Goldman Sachs and private equity at Vista Equity Partners, Tess is applying institutional-grade financial logic to a human problem. In this episode, we explore how Clasp is moving the needle from "Turnover to Tenure" by connecting employers with clinicians before graduation and utilizing student loan repayment as a structural retention tool.

Should we think of AI as a co-intelligence and digital coworker rather than just a chatbot? Ethan Mollick, a professor at Wharton and author of numerous books including the New York Times bestseller “Co-Intelligence: Living and Working with AI,” says so. He joins WITHpod to discuss the practical application, adoption, and transformative impact of AI on work. Sign up for MS NOW Premium on Apple Podcasts to listen to this show and other MS podcasts without ads. You'll also get exclusive bonus content from this and other shows. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

MoneyWise is a Hampton podcast. Hampton is a private, vetted community for founders doing $3M or more in revenue. Apply at https://www.joinhampton.com/?utm_source=youtube&utm_medium=video&utm_campaign=yt051126.From Minecraft maps to $400k months — but the money isn't the story.Nathan May grew up in one of the poorest neighborhoods in Ohio. His mom made $32,000 a year. He never left the state until he was 18. At 15, he was selling custom Minecraft maps to famous YouTubers and making his first $100K. He went to Wharton, joined BCG, quit, and built one of the fastest-growing newsletter agencies in the country before turning 30.But the week he hit his first million dollars, his mom died. And he felt nothing.In this episode, Nathan gets brutally honest about what money actually gave him — and what it didn't. We go deep on the community he's built in New York with a group of founders sharing an office, a monthly revenue leaderboard, and the kind of real talk that doesn't happen anywhere else. He calls it the Media Mafia. He says it's changed his life more than any dollar amount ever has.We also get into:Growing up in poverty and never leaving Ohio until 18How a Minecraft addiction became his first real businessLeaving a six-figure BCG career to bet on himselfBuilding a $1M ARR agency in under a year with 1,000 newsletter subscribersHis actual net worth, his $10M target, and why he keeps almost no cashWhy he thinks the wealthiest people he knows are often the least happyTimestamps00:00 - Cold open00:58 - Introducing Nathan May01:23 - Small talk / how Nathan starts his day02:32 - The agency, the numbers, how life has changed03:24 - Growing up poor in Ohio — never left the state until 1805:35 - He originally wanted to be an actor06:04 - The Minecraft business: how a video game addiction made him $100K at 1509:05 - Wharton, Wall Street culture shock, and the path to BCG10:36 - What BCG actually changed about his life12:01 - Building the agency: newsletters, Schwarzenegger, and why it felt like video games again15:32 - His real relationship with money: checking account, savings, leverage strategy16:52 - The $10M number: how he used ChatGPT to find his "enough"18:34 - The Media Mafia: seven founders, one office, a monthly revenue leaderboard20:31 - Being at the cusp — exciting, terrifying, or both?23:07 - Why IRL community is the highest-leverage thing a founder can build26:03 - What Hampton means to him27:31 - His mom's passing, the $1M milestone, and why none of it felt like anything29:24 - Can you be successful without community?31:39 - What's next and closing thoughtsMoneyWise is the podcast where high-net-worth founders get radically transparent about how they actually make, spend, invest, and think about money. Hosted by Daniel Berk and presented by Hampton.Sponsors:Daily Body Coach - achieve your dream body with https://moneywise.dailybodycoach.com

AI is rapidly reshaping the MBA - and some business schools are racing ahead faster than others. In this episode, who leads the charge and what questions MBA applicants should ask about AI adoption.

In this faculty spotlight, Professor Aimee Barbeau of Gies College of Business explains how she introduces first-year students to business through ethics, experiential learning, and real-world impact projects. She challenges common misconceptions about capitalism by framing business as a value-creating, ethical practice and shows how tools like AI and hands-on corporate partnerships help students build practical skills and rethink the role of business in society.

Send us Fan MailIn this epsiode: Angela and Christi welcome Lydia Miller, fourth-generation owner of her family construction business and its first female leader, who shares her path from University of Pennsylvania lacrosse and Navy ROTC to serving on warships and in Pentagon intelligence, earning a Wharton executive MBA, joining the family firm, and taking full ownership two years ago. Lydia explains transforming a decades-old business into a scalable, process-driven organization through correct sequencing and a “people ladder” that builds from admin and financial foundations to delivery, marketing, sales, and leadership with leaders at each rung. She recounts leading as one of eight women on a 400-person ship, emphasizing bold curiosity, learning in the field, mission focus, and how sports build command presence. She describes Miller Tech's aggressive AI use to gain speed while avoiding private-data risks, and outlines the stage-gated “Miller methodology” across pre-construction, construction, and launch to deliver consistent, surprise-free client experiences.Support the show

The day before Mother's Day, we're looking at the mixed emotions many moms feel: love, gratitude… and exhaustion. Dr. Corinne Low, a Wharton professor and author of Having It All, explains what the data shows about the pressures of modern motherhood — from how much time parents spend with kids today compared to decades ago, to the invisible work many moms still carry. Plus, how families can think differently about outsourcing help, and how even overwhelmed moms can make sure joy is still on the to-do list.   Learn more about our guest(s): https://www.theNewsWorthy.com/shownotes Join us again for our 10-minute daily news roundups every Mon-Fri!  Become an INSIDER and get ad-free episodes here: https://www.theNewsWorthy.com/insider Get The NewsWorthy MERCH here: https://www.theNewsWorthy.com/merch Sponsors: Get 20% off your DeleteMe plan when you go to JoinDeleteMe.com/newsworthy and use promo code NEWSWORTHY at checkout! Refresh your everyday with luxury you'll actually use. Head to Quince.com/newsworthy for free shipping on your order and 365-day returns! To advertise on our podcast, please email: ad-sales@libsyn.com

In this clip from Transfer Insight, Dan is joined by Liverpool Journalist David Lynch to discuss links to Crystal Palace's Adam Wharton and the likelihood of The Reds signing him this summer. Hosted on Acast. See acast.com/privacy for more information.

AI – and coverage of it – is everywhere. But what is artificial intelligence, really, beyond the buzzword? Each week, in a special new miniseries - ‘The AI End Game' - Chris Hayes is joined by preeminent experts on AI and its effects to help make sense of this revolutionary time in history. The series will feature in-depth conversations with experts, including: The Atlantic journalist Derek Thompson; professor at Wharton and New York Times bestselling author Ethan Mollick, professor of psychology at UC Berkeley and member of the Berkeley AI Research Group Alison Gopnik; former co-lead of the Ethical Artificial Intelligence Team at Google and co-founder of Black in AI Timnit Gebru; philosopher and cognitive scientist David Chalmers; author, host of the “Better Offline” podcast and writer of the “Where's Your Ed At” newsletter, Ed Zitron; The New York Times journalist and author, Michael Pollan, and more. The first episode is available now wherever you get your podcasts.  Want more of Rachel? Check out the "Rachel Maddow Presents" feed to listen to all of her chart-topping original podcasts.To listen to all of your favorite MS podcasts without ads, sign up for MS NOW Premium on Apple Podcasts. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

AI – and coverage of it – is everywhere. But what is artificial intelligence, really, beyond the buzzword? Each week, in a special new miniseries - ‘The AI End Game' - Chris Hayes is joined by preeminent experts on AI and its effects to help make sense of this revolutionary time in history. The series will feature in-depth conversations with experts, including: The Atlantic journalist Derek Thompson; professor at Wharton and New York Times bestselling author Ethan Mollick, professor of psychology at UC Berkeley and member of the Berkeley AI Research Group Alison Gopnik; former co-lead of the Ethical Artificial Intelligence Team at Google and co-founder of Black in AI Timnit Gebru; philosopher and cognitive scientist David Chalmers; author, host of the “Better Offline” podcast and writer of the “Where's Your Ed At” newsletter, Ed Zitron; The New York Times journalist and author, Michael Pollan, and more. The first episode is available now wherever you get your podcasts.  Sign up for MS NOW Premium on Apple Podcasts to listen to this show and other MS podcasts without ads. You'll also get exclusive bonus content from this and other shows. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

#1002 | Ed, Dharnish and Daniel react to United's 3–2 win over Liverpool and debate whether “underlying metrics” matter without context? United are succeeding on fine margins with elite attackers and reduced chances conceded under Michael Carrick. They break down Carrick's approach: bypassing the opposition press, sitting compact in a mid-block, and attacking quickly in transition. With Champions League secured and Carrick seen as favourite for the job, we discuss how his football might evolve toward more control while keeping his tactical flexibility. The focus turns to summer recruitment, especially finding the right midfield partner for Kobbie Mainoo, with quick-fire takes on targets like Wharton, Anderson, Baleba, Tchouaméni and Mateo Fernandez. 00:00 Introduction 01:24 Are the Underlying Metrics Bad? 04:38 Third Next Season - Acceptable? 08:31 Liverpool Match Analysis 10:20 Carrick's Game Model 13:52 How Does Carrick Evolve the Team? 22:53 Transfer Targets and Midfield Profiles 26:00 Rapid Fire Transfer Round If you are interested in supporting the show and accessing a weekly exclusive bonus episode, check out our Patreon page or subscribe on Apple Podcasts. Supporter funded episodes are ad-free. NQAT is available on all podcast apps and in video on YouTube. Hit that subscribe button, leave a rating and write a review on Apple or Spotify. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Send us Fan MailThere's a version of you that you know you're capable of becoming… So what's actually holding you back?In this powerful episode, Kaitlyn sits down with Dr. Daryll Wharton, keynote speaker, mindset coach, and hypnotherapist, to uncover the real reason so many women feel stuck—even when they “know what to do.” Together, they dive into the subconscious patterns, inherited beliefs, and hidden narratives that quietly shape your identity and keep you playing small.Dr. Daryll shares her incredible personal journey, her approach to rewiring the mind, and simple yet powerful shifts that can help you start showing up as your next-level self—starting today. From confidence and discipline to identity and self-worth, this conversation will challenge the way you think about transformation.If you've ever felt like you're holding yourself back, this episode will open your eyes in a whole new way.

Thinking about a dual-degree MBA? In this episode, we break down the most popular pairings – from MBA/MPP to MBA/JD – who they make sense for, costs and career trade-offs.

Most people think crossing the line is a single decision. It's not. AJ sits down with Tom Hardin to unpack how small ethical compromises compound over time — and how pressure, ambition, and environment can quietly push anyone further than they ever expected. From feeling like an outsider at Wharton to navigating Wall Street culture, insider information, and the pull of status, this episode reveals how rationalization, incentives, and relationships shape behavior more than we think. It's a candid look at decision-making under pressure — and how quickly things can spiral when no one is asking hard questions. Chapters00:00 – From outsider to Wall Street ambition10:00 – Pressure, performance, and fitting in20:00 – The first ethical lines start to blur30:00 – Insider information and rationalization40:00 – Status, relationships, and escalation55:00 – The FBI, getting caught, and fallout01:10:00 – Cooperation, identity shift, and consequences01:22:00 – Lessons on environment, incentives, and integrity A Word From Our Sponsors Stop being over looked and unlock your X-Factor today at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠unlockyourxfactor.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  The very qualities that make you exceptional in your field are working against you socially.  Visit the ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠artofcharm.com/intel ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠for a social intelligence assessment and discover exactly what's holding you back. If you've put off organizing your finances, Monarch is for you. Use code CHARM at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠monarch.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ in your browser for half off your first year.  Indulge in affordable luxury with Quince. Upgrade your wardrobe today at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠quince.com/charm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ for free shipping and hassle-free returns. Grow your way - with Headway! Get started at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠makeheadway.com/CHARM ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠and use my code CHARM for 25% off. This year, skip breaking a sweat AND breaking the bank. Get your summer savings and shop premium wireless plans at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠mintmobile.com/charm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Curious about your influence level?  Get your Influence Index Score today! Take this 60-second quiz to find out how your influence stacks up against top performers at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠theartofcharm.com/influence⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Episode resources: ⁠⁠https://joshuabandoch.com/⁠⁠ Check in with AJ and Johnny! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠AJ on LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Johnny on LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠AJ on Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Johnny on Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Art of Charm on Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Art of Charm on YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Art of Charm on TikTok ethics, decision making, insider trading, workplace culture, pressure, rationalization, leadership, incentives, human behavior, career risk, accountability, social dynamics Learn more about your ad choices. Visit megaphone.fm/adchoices

In this week's MBA Admissions podcast we began by discussing the current state of the MBA admissions season. We are continuing to see MBA programs release their final decisions. This upcoming week, UVA / Darden, Berkeley / Haas, Texas / McCombs, Cornell / Johnson, INSEAD, Duke / Fuqua, Vanderbilt / Owen and Michigan State / Broad are releasing final decisions. A few MBA programs are also continuing to their next admissions rounds, including CMU / Tepper and IESE. Graham highlighted upcoming Clear Admit events. On May 11, Clear Admit is hosting our in-person admissions event in Atlanta. Most top MBA programs are scheduled to attend. We are also hosting several Application Overview events in May, on May 19 and 20, and May 26 and 27. Signups for these events are here: https://www.clearadmit.com/events Graham continued with the Real Humans Alumni series. This week focuses on three alumni from Fuqua / National Grid Ventures, Haas / Adobe and Johnson / Bain. Graham also highlighted a recently published Fridays from the Frontlines article written by a student from LBS regarding their Global Experience in China. For this week, for the candidate profile review portion of the show, Alex selected three DecisionWire entries: This week's first MBA admissions candidate is deciding between McDonough and Said. They want to return to the World Bank focusing on development finance. This week's second MBA applicant has offers from Tuck, Sloan and Wharton. They are focused on health care, tech and venture capital. This week's final MBA candidate is deciding Fuqua, Anderson and Marshall. They want to do consulting in Los Angeles. This episode was recorded in Paris, France and Cornwall, England. It was produced and engineered by the fabulous Dennis Crowley in Philadelphia, USA. Thanks to all of you who've been joining us and please remember to rate and review this show wherever you listen!

We're excited to announce a new special WITHpod series, "The AI End Game: Power, Profit, and Progress." AI – and coverage of it – is everywhere. But what is artificial intelligence, really, beyond the buzzword? Each week, we'll be joined by preeminent experts on AI and its effects to help make sense of this revolutionary time in history. The series will feature in-depth conversations with experts, including: The Atlantic journalist Derek Thompson; professor at Wharton and New York Times bestselling author Ethan Mollick, professor of psychology at UC Berkeley and member of the Berkeley AI Research Group Alison Gopnik; former co-lead of the Ethical Artificial Intelligence Team at Google and co-founder of Black in AI Timnit Gebru; philosopher and cognitive scientist David Chalmers; author, host of the “Better Offline” podcast and writer of the “Where's Your Ed At” newsletter, Ed Zitron; The New York Times journalist and author, Michael Pollan, and more.    Sign up for MS NOW Premium on Apple Podcasts to listen to this show and other MS podcasts without ads. You'll also get exclusive bonus content from this and other shows. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We're excited to announce a new special WITHpod series, "The AI End Game: Power, Profit, and Progress." AI – and coverage of it – is everywhere. But what is artificial intelligence, really, beyond the buzzword? Each week, we'll be joined by preeminent experts on AI and its effects to help make sense of this revolutionary time in history. The series will feature in-depth conversations with experts, including: The Atlantic journalist Derek Thompson; professor at Wharton and New York Times bestselling author Ethan Mollick, professor of psychology at UC Berkeley and member of the Berkeley AI Research Group Alison Gopnik; former co-lead of the Ethical Artificial Intelligence Team at Google and co-founder of Black in AI Timnit Gebru; philosopher and cognitive scientist David Chalmers; author, host of the “Better Offline” podcast and writer of the “Where's Your Ed At” newsletter, Ed Zitron; The New York Times journalist and author, Michael Pollan, and more.  Want more of Chris? Download and follow his podcast, “Why Is This Happening? The Chris Hayes podcast” wherever you get your podcasts.To listen to this show and other MS podcasts without ads, sign up for MS NOW Premium on Apple Podcasts. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Robyn Barriffe, DNP, RN, NEA-BC, CCRN-K, didn't set out to become a nurse. A single mother of four, she felt something like a divine nudge and went for it. More than two decades later, having led nursing teams at NorthShore Health System in Chicago, Novant Health in North Carolina, and most recently Atrium Health Pineville, where she guided the hospital to its first-ever ANCC Pathway to Excellence designation, Robyn has just taken on the CNO role at Ascension St. Vincent's Riverside in Jacksonville, Florida. Across every institution, her philosophy has remained the same: the organization is the patient, and quality metrics, teammate engagement, and patient experience are vital signs.  Now, as a Johnson & Johnson Nurse Innovation Fellow, Robyn has discovered a framework she believes the profession has been missing. The fellowship, led by Marion Leary, PhD, MPH, RN, of Penn Nursing, pairs human-centered design methodology with Wharton leadership training and culminates in each team of fellows pitching a solution to a real problem inside their own health system.    For more information on the podcast bundles, visit ANA's Innovation Website at: https://www.nursingworld.org/practice-policy/innovation/education. Have questions or feedback for the SEE YOU NOW team? Future episode ideas? Contact us at: hello@seeyounowpodcast.com.

Jonathan Simon chats with Prema Formula 3 driver James Wharton about life in the fast lane, what a crash feels like, his injuries, secrets of the F3 world, friends in Formula 1, and more... on the latest episode of Missed Apex Podcast. Hosted on Acast. See acast.com/privacy for more information.

durée : 00:03:30 - Le Regard culturel - par : Lucile Commeaux - Grande découverte en ce printemps : le court roman "Été", d'Edith Wharton – qui reparaît dans une nouvelle traduction chez POL – raconte l'histoire d'une jeune Américaine en révolte contre la petitesse de la société dans laquelle elle vit.

Dan is here with the latest Liverpool news stories after Arne Slot spoke to the press ahead of the clash with Crystal Palace at Anfield. Hosted on Acast. See acast.com/privacy for more information.

In this episode, I sit down with Thomas Caleel — former Director of MBA Admissions at the Wharton School, founder of Admittedly, and one of the most clear-eyed voices in the college admissions space. This one is personal — I've got an 18-year-old headed to University of Arkansas in four months, and a sixth grader whose decisions today will quietly shape where he ends up ten years from now. Thomas opens the black box of college admissions and explains what's actually changed, what most parents are getting wrong, and what admissions officers are really looking for. The shift from well-rounded candidates to "vertical spikes" of deep passion and genuine interest is one of those things that sounds simple but changes everything about how you should be thinking about your kid's path right now. We talk about the right time to start, why the seventh-grade math assessment quietly matters more than most parents realize, how doing fewer things with real intentionality is more powerful than stacking clubs and activities, and why your child's college essay should tell their story — not yours. We also get into the financial reality most parents aren't prepared for — new federal loan caps, how to negotiate financial aid after admission, what Juno is and why it matters, and why sending your kid to a low-tier private college that costs $50,000 a year is something Thomas calls criminal. And he gives a refreshingly honest answer to whether college is actually worth it.   Timeline Summary [0:00] Introduction to the Dad Edge mission and the movement to raise leaders of families and communities [1:02] Larry's 18-year-old is leaving for University of Arkansas — and Thomas's son is heading to NYU [2:45] When change goes according to plan — and why it hits harder than you expect [4:45] What most parents are missing — the pressure cooker, the doom race, and why more is not always more [5:56] Why admissions is a black box — and why bad information fills that vacuum [7:23] Thomas's background — former Director of MBA Admissions at Wharton, 20 years shaping admissions strategy globally [9:05] How college admissions has changed — from well-rounded candidates to vertical spikes of deep passion [10:49] Why schools now prioritize socioeconomic diversity — and what full ride programs actually look like [11:37] What the internet did to admissions — 50,000 applicants where there used to be 8,000, and rates under 3% at Yale [12:00] Do fewer things intentionally and well — the sneakerhead who got into Stanford [15:18] Why volunteering doesn't help anymore if your kid doesn't actually care about it [17:31] How grit, initiative, and unglamorous jobs stand out just as much as expensive summer programs [19:29] The most common question Thomas hears — when should we start? [19:51] The seventh-grade math assessment that quietly determines whether your kid can pursue STEM majors [22:41] Middle school is for exploration — you don't need to pick a direction, just stay warm on the fundamentals [24:11] What universities are really asking — not what do you want to do with your life, but what are you curious about right now [24:47] Why your kid won't tell you the truth — and why a neutral third party changes everything [29:47] How to have a real conversation with your kid about what they actually want [30:36] Listening without judgment — the parent who almost killed their child's essay by refusing to let them tell their real story [33:06] How to handle the "I want to study dance" conversation — without crushing them [35:45] Is college a scam? Thomas's honest, nuanced answer — and why the lottery ticket mentality is dangerous [37:20] Why low-tier private colleges charging $50,000 a year are, in his words, criminal [40:38] What's changed in the political arena — new federal loan caps and what they mean for families [41:51] Why the ROI conversation has to happen before you commit to a school [44:08] How to negotiate financial aid after you've been admitted — and why schools will sometimes find money [45:03] Juno — the collective bargaining platform that negotiates lower interest rates on student loans [48:01] What Admittedly is — former admissions officers, group coaching, weekly office hours, and accessible pricing   Five Key Takeaways Admissions has shifted from well-rounded to deeply interesting. A kid who does one thing with real passion and depth will stand out over a kid who stacks clubs and activities to check boxes. The seventh-grade math assessment quietly shapes whether your kid can pursue the majors they want. Start paying attention earlier than you think you need to. Your child's essay needs to tell their story — not your version of their story. Listen without judgment and let them lead. The financial conversation has to happen early and honestly. With new federal loan caps and rising tuition, the ROI of each school choice matters more than ever. College is not a binary decision. It can be great, but it's not the right path for everyone. Know your child, know their goals, and help them build the path that actually fits — not the one that looks right from the outside.   Links & Resources Dad Edge Business Boardroom: https://thedadedge.com/boardroom Admittedly website: https://admittedly.co Admittedly on Instagram and TikTok: @admittedly.co Juno student loan platform: https://joinjuno.com Episode Link & Resources (Episode 1467): https://thedadedge.com/1467   Closing If there's one message from this episode that stands out, it's this: the decisions your kid makes in middle school are already shaping where they'll end up — and most parents don't find that out until it's too late to do anything about it. Thomas Caleel has sat inside the room where these decisions get made. He knows what gets someone in and what gets them passed over. And the good news is that none of it requires privilege, expensive programs, or a perfect resume. It requires knowing your kid, helping them tell their real story, and starting the right conversations while there's still time to matter. If your kid is anywhere from sixth grade to senior year, this episode is required listening. Go out and live legendary.

Ste is here for the latest episode of Redmen Weekly. This week includes clips from The Final Word show following both Fulham & PSG, The Biased Football Podcast and Journo Insight. Hosted on Acast. See acast.com/privacy for more information.

In this clip from Journo Insight, Ste is joined by Paul Gorst to discuss links to Crystal Palace's Adam Wharton. Hosted on Acast. See acast.com/privacy for more information.

Big Tech is selling us an illusion. From draining local communities of millions of gallons of water for data centers to actively degrading human cognition, the "AI Revolution" is creating an epidemic of laziness and cognitive surrender. I'm joined by innovation theorist and author of "The Borrowed Mind" John Nosta to expose the catastrophic reality of AI brain rot. While elites promise artificial general intelligence and a tech utopia, the data tells a different story: AI chatbots are making users lazier, more easily manipulated, and less capable of critical thought. It's not a problem in AI itself, but in the way products are being deployed and marketed, which is designed to exploit the most vulnerable human desires to surrender to fantasy. We break down the shocking studies from MIT and Wharton, the truth behind the trillion-dollar Big Tech data center scam draining rural America's resources, and how to reclaim your independent thought in an era of engineered sycophancy and digital obsolescence. Learn more about your ad choices. Visit megaphone.fm/adchoices